Retatrutide is a triple-agonist (GLP-1, GIP, glucagon) while Mounjaro is a dual-agonist (GLP-1, GIP)
Once released, this fat becomes available for energy production
Swider is CEO and Chief AI Officer at RealActivity, where he leads clinical and administrative AI strategy for healthcare organizations
Diabetes Obes Metab 22(3):355364 Ruiz PLD, Stene LC, Bakken IJ, Hberg SE, Birkeland KI, Gulseth HL (2018) Decreasing incidence of pharmacologically and non-pharmacologically treated type 2 diabetes in Norway: a nationwide study
Some things a clinician can help with: Dose titration: Theyll start with a lower dose and build it steadily as your body adjusts
Healthcare providers typically monitor lipid panels at baseline and after 3-6 months to assess response, with subsequent monitoring individualized based on clinical context